Anticancer Therapies – News and Features

A new blood test may make it easier to measure and personalize 5-FU dosing for patients undergoing infusion chemotherapy regimens.

Study will evaluate satraplatin in patients with metastatic hormone-refractory prostate cancer previously treated with docetaxel.

Tests include response prediction to ovarian cancer treatment, predicting gastric cancer recurrence risk, and differentiation of small cell from non-small cell lung cancer.

Researchers have created a small molecule that stimulates nerve stem cells to begin maturing into nerve cells in culture.

Researchers are testing a new way to kill cancer cells selectively by attaching cancer-seeking antibodies to tiny carbon tubes.

Company reaches a sponsored research agreement with M. D. Anderson Cancer Center for the development of a new class of compounds that inhibit glycolysis.

Collaboration will seek to identify unique microRNA signatures that will predict risk of recurrence in lung cancer patients.

Genmab has initiated a Phase I/II study of zalutumumab in combination with irinotecan chemotherapy to treat colorectal cancer patients.

Results of phase II investigator-sponsored trial presented at ASCO show Investigational regimen active with 42 percent objective tumor responses.

Second Phase III Study of Avastin Plus chemotherapy shows improved progression-free survival in women with advanced HER2-negative breast cancer.